You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 29, 2025

Profile for Peru Patent: 20130780


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Peru Patent: 20130780

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
10,179,140 Jun 28, 2031 Exeltis Usa Inc DROSPIRENONE drospirenone
10,179,140 Jun 28, 2031 Exeltis Usa Inc SLYND drospirenone
10,603,281 Jun 28, 2031 Exeltis Usa Inc DROSPIRENONE drospirenone
10,603,281 Jun 28, 2031 Exeltis Usa Inc SLYND drospirenone
10,849,857 Jun 28, 2031 Exeltis Usa Inc DROSPIRENONE drospirenone
10,849,857 Jun 28, 2031 Exeltis Usa Inc SLYND drospirenone
10,987,364 Jun 28, 2031 Exeltis Usa Inc DROSPIRENONE drospirenone
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Analysis of Patent PE20130780: Scope, Claims, and Landscape in Peru

Last updated: July 30, 2025

Introduction
Patent PE20130780, filed and granted in Peru, represents a distinct patent within the regional intellectual property landscape. Examined through the lens of scope, claims, and subsequent patent environment, this analysis provides a comprehensive understanding essential for decision-makers evaluating market access, licensing, and competition strategies within Peru’s pharmaceutical patent regime.


Patent Overview and Context

Patent Number: PE20130780
Filing Date: [Exact date not provided, assumed 2013]
Grant Date: [Assumed 2014-2015 based on typical processing times]
Applicant/Assignee: [Not specified; likely an innovator or generic manufacturer]
Technology Field: Likely pharmaceutical, based on the patent’s classification (information necessary for accuracy).

Peru, as a TRIPS-compliant member, grants patents that typically last 20 years from the filing date. The local patent landscape for pharmaceuticals is characterized by a modest number of patents, with an emphasis on chemical compounds, formulations, and methods of use.


Scope and Claims Analysis

1. The Scope of the Patent

The scope of PE20130780 frames the extent of exclusivity granted over the claimed invention. A well-defined scope limits competitors' overlap and ensures enforceability.
Given standard patent application structures, the scope likely encompasses:

  • Chemical compounds or formulations relevant to therapeutic use.
  • Method of manufacturing or specific treatment protocols.
  • Use claims specific to the application of a compound or formulation.

Key Point: The scope hinges critically upon the wording of independent claims and their respective fall within a language of broad or narrow coverage.

2. Claims Analysis

Claims in pharmaceutical patents typically include:

  • Product claims: Covering the chemical entity itself.
  • Use claims: Covering a particular therapeutic use.
  • Process claims: Covering the method of synthesis.
  • Formulation claims: Covering compositions with specific excipients or dosage forms.

In PE20130780, the likely structure involves:

  • Independent Claims: Broad claims covering the chemical compound or its use.
  • Dependent Claims: Narrower claims specifying particular modifications or formulations.

Assessment:

  • Claim Breadth: Narrow claims limit enforceability but ensure strong validity; broad claims maximize market control but carry higher invalidity risk.
  • Novelty and Inventive Step: The claims must demonstrate novelty against prior art, particularly existing patents or publications within Peru or internationally.

3. Claim Language and Legal Robustness

The clarity and definiteness of claim language impact enforceability. Precise chemical nomenclature, specific ranges, or ratios bolster patent strength, whereas overly broad, vague claims risk invalidation or easy design-around by competitors.


Patent Landscape in Peru for PE20130780

1. Regional and International Patent Environment

Peru’s patent landscape is influenced by regional filings through agreements such as:

  • Andean Community (CAN): Harmonized patent regulations among member states.
  • PCT System: Allows for international patent applications that can be extended to Peru.

Key Observations:

  • Overlap with International Patents: Many pharmaceutical patents filed via PCT include Peru as designated country.
  • Local Innovation: Although the Peruvian patent system is less crowded than the U.S. or EU, local filings tend to cluster around significant therapeutic classes.

2. Competitive Landscape

  • Active Patent Holders: Multinational pharmaceutical companies often file patents for molecules, formulations, or therapeutic methods.
  • Patent Challenges and Litigation: Patent validity contests remain relatively infrequent but are critical for market exclusivity.

3. Patent Life and Market Entry

Given that patents generally last 20 years from the filing date, PE20130780’s remaining enforceability depends on the filing and grant dates. Post-grant, patent holders can prevent generic entry barring licensing or patent challenges.


Implications for Stakeholders

For Innovators

  • Protecting broad, well-defined claims can safeguard market share.
  • Monitoring regional patent filings ensures IP rights are maintained and enforceable.

For Generics

  • Technical and legal analysis of patent PE20130780 reveals potential freedom-to-operate issues or opportunities for designing around the patent scope.

For Patent Attorneys and R&D

  • Focus on ensuring claims are precise yet broad enough to encompass evolving formulations or use cases.
  • Legally robust claims provide leverage in licensing negotiations and dispute resolution.

Key Takeaways

  • Scope Precision Is Critical: Well-crafted claims that balance breadth and validity enhance enforceability.
  • Regional Patent Landscape Is Dynamic: Peru’s pharmaceutical patents frequently build on international filings; staying vigilant for overlapping IP rights is essential.
  • Patent Validity and Market Exclusivity: Duration, patent prosecution history, and prior art influence the strength of PE20130780.
  • Legal Strategies Must Be Informed by Landscape: Understanding existing patents and pending applications enables proactive licensing or design-around strategies.
  • Continuous Monitoring Is Recommended: The patent landscape evolves, especially with parallel filings via PCT; ongoing analysis ensures strategic positioning.

FAQs

1. What is the typical lifespan of patent PE20130780 in Peru?
A standard patent is valid for 20 years from the filing date. Exact expiry depends on the original filing and any patent term adjustments.

2. How do claims define the scope of patent PE20130780?
Claims specify the protected invention, including chemical compositions, methods, or uses; their phrasing determines the patent’s breadth and enforceability.

3. Can competitors legally develop similar drugs if they avoid infringing claims?
Yes, provided they do not infringe the specific claim language, especially if they modify the compound, formulation, or method within permissible limits.

4. What is the impact of regional patent agreements on PE20130780?
Regional agreements like those within the Andean Community facilitate patent recognition and enforcement across member states, enhancing market protection.

5. How does Peru’s patent landscape influence innovation strategies?
A relatively modest patent environment necessitates strategic patenting, focusing on producing robust claims and monitoring potential infringements actively.


References
[1] Peruvian Patent Office (INDECOPI), Official Patent Database.
[2] World Intellectual Property Organization (WIPO), Patent Landscape Reports.
[3] TRIPS Agreement, WTO.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.